• RNA Pol II Inhibition Triggers Apoptosis Independent of Tran

  2026-06-30

  Harper et al. (2025) reveal that cell death following RNA polymerase II (Pol II) inhibition is not due to general loss of transcription, but is instead activated by a specific signaling pathway sensing the depletion of hypophosphorylated RNA Pol IIA. This new mechanistic insight redefines how regulated cell death is triggered in response to transcriptional inhibitors—an advance with implications for oncology, cell biology, and translational research.

• Escalating Macrolide Resistance in Pediatric Mycoplasma pneu

  2026-06-29

  A recent study documents a 100% resistance rate to erythromycin and azithromycin among Mycoplasma pneumoniae isolates from children in Beijing, highlighting the rising challenge of macrolide-resistant infections. Notably, the research demonstrates that acetylspiramycin (Spiramycin B), a 16-membered macrolide, retains lower minimum inhibitory concentrations compared to standard macrolides, underscoring its relevance in antimicrobial resistance research and susceptibility testing.

• Vidarabine Monohydrate (C6377): Reliable Antiviral Assay Wor

  2026-06-29

  This article provides a scenario-based, data-driven guide to using Vidarabine monohydrate (SKU C6377) for robust antiviral and cytotoxicity assays. Grounded in real laboratory challenges, it addresses solubility, reproducibility, and product selection, demonstrating how the high-purity formulation from APExBIO supports consistent results in DNA replication interference and herpes simplex virus research.

• SIRT1/2 Inhibitor IV (cambinol): Bridging Metabolic Signalin

  2026-06-28

  Explore how SIRT1/2 Inhibitor IV (cambinol) uniquely enables researchers to dissect the intersection of metabolic and epigenetic regulation in both oncology and CNS injury. This article delivers advanced insights, protocol guidance, and practical impact for translational models.

• MLN4924 HCl Salt: Disrupting Neddylation to Decode Protein F

  2026-06-27

  Explore the advanced mechanistic and translational impact of MLN4924 HCl salt, a potent NEDD8-activating enzyme inhibitor. This article uniquely ties neddylation disruption to viral immune evasion and precise assay optimization, delivering actionable insights for cancer biology and inflammation research.

• CHAP Model Simplifies Bleeding Risk Prediction in Extended V

  2026-06-26

  The referenced study introduces the CHAP model, a streamlined tool for predicting major bleeding during extended anticoagulation in patients with unprovoked or weakly provoked venous thromboembolism (VTE). By using continuous predictors, the CHAP model matches or surpasses the performance of modified established risk scores, potentially enabling more individualized clinical decisions, though external validation is still necessary.

• HyperScript III RT SuperMix for qPCR: Precision in Low-Input

  2026-06-26

  Explore how HyperScript III RT SuperMix empowers high-fidelity cDNA synthesis from low-concentration and high-GC RNA, enabling sophisticated gene expression analysis by qPCR. This article unveils advanced protocol strategies and the impact of recent CRC biomarker research.

• T-5224 (C-Fos/AP-1 Inhibitor): Precision Modulation of AP-1

  2026-06-25

  Explore how T-5224, a selective C-Fos/AP-1 inhibitor, enables advanced modulation of inflammatory and osteoclastogenic pathways. This article uniquely bridges molecular mechanisms, new neuroinflammatory insights, and experimental strategy for impactful arthritis and pain research.

• CD28-ARS2 Axis Drives PKM Splicing for CD8+ T Cell Flexibili

  2026-06-25

  The reference study identifies the CD28-ARS2 signaling axis as a pivotal driver of alternative splicing in activated CD8+ T cells, promoting the PKM2 isoform of pyruvate kinase and enabling metabolic flexibility crucial for antitumor immunity. These findings clarify how co-stimulatory signaling rewires T cell metabolism, offering new insights into immunometabolic regulation relevant to cancer therapy.

• Malate in TCA Cycle Research: Protocols, Innovations & Troub

  2026-06-24

  Malate ((S)-2-hydroxysuccinic acid) is a central metabolic intermediate critical for dissecting TCA cycle dynamics and immunometabolic crosstalk in cancer and mitochondrial studies. This article translates recent reference breakthroughs into actionable workflows, troubleshooting strategies, and comparative insights—empowering researchers to enhance reproducibility and depth in metabolic assays with APExBIO’s malate.

• WAY-100635: Illuminating 5-HT1A Antagonism in Pain and Emoti

  2026-06-23

  Discover the scientific depth of WAY-100635, a potent 5-HT1A receptor antagonist, and its unique applications in dissecting serotonergic mechanisms underlying pain and affect. This article delivers fresh insights and protocol strategies beyond standard workflows.

• Enhancing Protein Purification with Hexa His Tag Peptide Wor

  2026-06-23

  The Hexa His tag peptide streamlines immunoprecipitation and protein purification, enabling antibody-free elution and high-yield recovery of His-tagged proteins. This article details best practices, troubleshooting, and advanced applications for maximizing reproducibility and purity in recombinant protein workflows.

• SCUBE3 Antibody Targeting Suppresses Tumor Growth and Immune

  2026-06-22

  This study identifies secretory protein SCUBE3 as a central driver of tumor progression and therapy resistance, enabling immune evasion through epigenetic modulation. Neutralizing SCUBE3 with a specifically engineered antibody disrupts oncogenic signaling and restores antitumor immunity, offering a promising strategy for pan-cancer therapy.

• Preclinical Advances of Anlotinib: Selective VEGFR2 Inhibiti

  2026-06-22

  This reference study establishes anlotinib hydrochloride as a highly potent and selective multi-target tyrosine kinase inhibitor, with particular strength against VEGFR2-mediated angiogenesis. The findings detail its superior efficacy, selectivity, and in vivo antitumor effects, supporting its value for mechanistic cancer research and comparative evaluation in preclinical models.

• Penicillin G Sodium: Protocol Optimization for Gram-Positive

  2026-06-21

  Penicillin G Sodium streamlines the inhibition of bacterial cell wall biosynthesis in Gram-positive models, offering robust reproducibility and high sensitivity across infection and contamination control workflows. Discover how APExBIO’s high-purity product, data-driven protocol enhancements, and troubleshooting insights ensure optimal outcomes from initial setup to advanced comparative applications.

452 records 13/31 page Previous Next First page 上5页 1112131415 下5页 Last page